| Name | Title | Contact Details |
|---|---|---|
Kevin Duvall |
ARPA-H Chief Information Officer | Profile |
Kevin Duvall |
Acting Chief Technology Officer and Chief Information Officer | Profile |
KindredBio is focused on bringing groundbreaking products and innovative new technologies to veterinary medicine, because we believe our animal companions deserve the same kinds of safe and effective medicines that human family members enjoy.
resTORbio, Inc. is a clinical stage company, developing medicines to treat aging-related diseases and conditions. resTORbio`s lead program targets the mechanistic target of rapamycin complex 1 (mTORC1) pathway to treat aging-related diseases and conditions. Initially, resTORbio is focused on developing medicines that address conditions caused by immunosenescence, the decline in immune function due to aging. resTORbio has initiated a Phase 2b trial for its lead product candidate, RTB101, evaluating its potential to reduce the incidence of respiratory tract infections (RTI) in elderly individuals at increased risk of RTI-related morbidity and mortality. resTORbio`s lead program is built upon two Phase 2a clinical studies demonstrating promising safety and efficacy results in almost 500 elderly individuals.
Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.
Crescendo Bioscience is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.